Company intelligence / Profile preview

Minerva Neurosciences, Inc.

Cambridge*, Massachusetts, United Statesminervaneurosciences.com ↗

Ownership: Public · NERV
Employees: ~45
Development stage: NDA

Overview

Minerva Neurosciences’ lead candidate roluperidone has completed Phase 3 trials for the treatment of negative symptoms in schizophrenia. The company has demonstrated bioequivalence between its clinical and planned commercial formulations and has submitted a New Drug Application (NDA) to the FDA. No pharmacological agent is currently approved for this indication, representing a significant unmet need. Other pipeline programs are at earlier stages or have been deprioritized.

Therapeutic areas: PsychiatryNeurology
Modalities: small molecules
Industry: Biotech

Drug pipeline

4 assets

roluperidone

3 more assets in the full pipeline.

Request access →

Partnerships

Janssen Pharmaceutical Companies of Johnson & Johnson—co-development/licensing agreement for seltorexant/MIN‑202 in certain territoriesBoehringer Ingelheim—private placement financing partner for roluperidone development

Financials

Market cap: $193.8M
Total revenue: $0
Enterprise value: $118.5M

Beyond the preview

Go deeper on Minerva Neurosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minerva Neurosciences, Inc..

Explore the full profile